Xtant Medical (XTNT) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 revenue of $31.5 million and full-year revenue of $117.3 million, reflecting 12% quarter-over-quarter and 28% year-over-year growth, driven by the integration of Surgalign and strong biologics performance.

• Positive adjusted EBITDA of $438,000 in Q4, despite a $1.5 million inventory write-off related to the Surgalign acquisition.

• Net loss for 2024 was $16.4 million, compared to net income of $660,000 in 2023, which included an $11.7 million bargain purchase gain.

• Operating expenses were reduced by over $5 million on an annualized basis since Q3 2024, with some savings reinvested for growth and a 13% headcount reduction.

• Focused on vertical integration of biologics and rationalization of hardware lines to improve profitability and efficiency.

Financial highlights

• Q4 2024 revenue: $31.5 million (up 12% year-over-year); full-year 2024 revenue: $117.3 million (up 28% year-over-year).

• Q4 gross margin: 50.8% (down from 61% in Q4 2023), impacted by inventory write-off and reduced production yields.

• Full-year gross margin: 58.2% (down from 60.8% in 2023), primarily due to reduced production throughput and inventory write-offs.

• Q4 net loss: $3.2 million ($0.02/share), improved from $4.3 million loss in Q4 2023; full-year net loss: $16.4 million ($0.12/share), compared to $660,000 net income in 2023.

• Cash, equivalents, and restricted cash at year-end: $6.2 million; inventory: $38.6 million; $4.2 million available under revolving credit facilities.

Outlook and guidance

• 2025 revenue guidance: $126–130 million (7–11% growth), with mid-double-digit growth in biologics and flat to modestly down hardware revenue.

• Free cash flow generation is expected to begin in the second half of 2025, with no need for additional external capital.

• Gross margin expected to improve by 4–5 points by Q4 2025, driven by new product launches and operational efficiencies.

• Cost savings from integration and headcount reductions already impacting Q4, with further benefits expected in Q1 2025.